Catalyst

Slingshot members are tracking this event:

AFM13 Phase 2a interim data due 2Q 2016 in Hodgkin lymphoma (HL) for Affimed’s lead candidate

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AFMD

100%

Additional Information

Additional Relevant Details Update on Nov 8 2016: AFM13 abstract presentation expected on Dec 3 2016.
http://www.affimed.c...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 06, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Afm13, Phase 2a Interim Data, 2q 2016, Hodgkin Lymphoma, Lead Candidate, Bispecific Cd30/cd16a Nk-cellengaging Tandab